Since the first reports in the mid-80s of effective immunotherapy with IFNα and subsequently IL-2 for metastatic RCC, little progress has been really made and response rates are still plateauing around 15% in large multicentre trials (Hernberg et al, 1999). This evidence concerns the gene IL2 and renal cell adenocarcinoma.